Literature DB >> 18358721

Synthesis and antitubercular activity of 7-(R)- and 7-(S)-methyl-2-nitro-6-(S)-(4-(trifluoromethoxy)benzyloxy)-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazines, analogues of PA-824.

Xiaojin Li1, Ujjini H Manjunatha, Michael B Goodwin, John E Knox, Christopher A Lipinski, Thomas H Keller, Clifton E Barry, Cynthia S Dowd.   

Abstract

Nitroimidazoles such as PA-824 and OPC-67683 are currently in clinical development as members of a promising new class of therapeutics for tuberculosis. While the antitubercular activity of these compounds is high, they both suffer from poor water solubility thus complicating development. We determined the single crystal X-ray structure of PA-824 and found a close packing of the nitroimidazoles facilitated by a pseudoaxial conformation of the p-trifluoromethoxybenzyl ether. To attempt to disrupt this tight packing by destabilizing the axial preference of this side chain, we prepared the two diastereomers of the 7-methyl-nitroimidazo-oxazine. Determination of the crystal structure of the 7-(S)-methyl derivative (5, cis) revealed that the benzylic side chain remained pseudoaxial while the 7-(R)-methyl derivative (6, trans) adopted the desired pseudoequatorial conformation. Both derivatives displayed similar activities against Mycobacterium tuberculosis, but neither showed improved aqueous solubility, suggesting that inherent lattice stability is not likely to be a major factor in limiting solubility. Conformational analysis revealed that all three compounds have similar energetically accessible conformations in solution. Additionally, these results suggest that the nitroreductase that initially recognizes PA-824 is somewhat insensitive to substitutions at the 7-position.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18358721      PMCID: PMC2408714          DOI: 10.1016/j.bmcl.2008.03.011

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  13 in total

Review 1.  Physicochemical profiling in drug research: a brief survey of the state-of-the-art of experimental techniques.

Authors:  A Avdeef; B Testa
Journal:  Cell Mol Life Sci       Date:  2002-10       Impact factor: 9.261

Review 2.  Drug polymorphism and dosage form design: a practical perspective.

Authors:  Dharmendra Singhal; William Curatolo
Journal:  Adv Drug Deliv Rev       Date:  2004-02-23       Impact factor: 15.470

Review 3.  Prospects for new antitubercular drugs.

Authors:  Ken Duncan; Clifton E Barry
Journal:  Curr Opin Microbiol       Date:  2004-10       Impact factor: 7.934

4.  Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles.

Authors:  Hirofumi Sasaki; Yoshikazu Haraguchi; Motohiro Itotani; Hideaki Kuroda; Hiroyuki Hashizume; Tatsuo Tomishige; Masanori Kawasaki; Makoto Matsumoto; Makoto Komatsu; Hidetsugu Tsubouchi
Journal:  J Med Chem       Date:  2006-12-28       Impact factor: 7.446

5.  Filipin III: Configuration Assignment and Confirmation by Synthetic Correlation.

Authors:  Timothy I. Richardson; Scott D. Rychnovsky
Journal:  J Org Chem       Date:  1996-06-26       Impact factor: 4.354

6.  A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.

Authors:  C K Stover; P Warrener; D R VanDevanter; D R Sherman; T M Arain; M H Langhorne; S W Anderson; J A Towell; Y Yuan; D N McMurray; B N Kreiswirth; C E Barry; W R Baker
Journal:  Nature       Date:  2000-06-22       Impact factor: 49.962

7.  Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models.

Authors:  Anne J Lenaerts; Veronica Gruppo; Karen S Marietta; Christine M Johnson; Diane K Driscoll; Nicholas M Tompkins; Jerry D Rose; Robert C Reynolds; Ian M Orme
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

8.  In vitro and in vivo activities of the nitroimidazole CGI 17341 against Mycobacterium tuberculosis.

Authors:  D R Ashtekar; R Costa-Perira; K Nagrajan; N Vishvanathan; A D Bhatt; W Rittel
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

9.  Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis.

Authors:  L G Wayne; H A Sramek
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

10.  OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice.

Authors:  Makoto Matsumoto; Hiroyuki Hashizume; Tatsuo Tomishige; Masanori Kawasaki; Hidetsugu Tsubouchi; Hirofumi Sasaki; Yoshihiko Shimokawa; Makoto Komatsu
Journal:  PLoS Med       Date:  2006-11       Impact factor: 11.069

View more
  16 in total

1.  Synthesis and evaluation of pretomanid (PA-824) oxazolidinone hybrids.

Authors:  David F Bruhn; Michael S Scherman; Aman P Singh; Lei Yang; Jiuyu Liu; Anne J Lenaerts; Richard E Lee
Journal:  Bioorg Med Chem Lett       Date:  2015-12-07       Impact factor: 2.823

2.  Structure-activity relationships of antitubercular nitroimidazoles. 3. Exploration of the linker and lipophilic tail of ((s)-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazin-6-yl)-(4-trifluoromethoxybenzyl)amine (6-amino PA-824).

Authors:  Joseph Cherian; Inhee Choi; Amit Nayyar; Ujjini H Manjunatha; Tathagata Mukherjee; Yong Sok Lee; Helena I Boshoff; Ramandeep Singh; Young Hwan Ha; Michael Goodwin; Suresh B Lakshminarayana; Pornwaratt Niyomrattanakit; Jan Jiricek; Sindhu Ravindran; Thomas Dick; Thomas H Keller; Veronique Dartois; Clifton E Barry
Journal:  J Med Chem       Date:  2011-07-26       Impact factor: 7.446

Review 3.  Nitroimidazoles for the treatment of TB: past, present and future.

Authors:  Tathagata Mukherjee; Helena Boshoff
Journal:  Future Med Chem       Date:  2011-09       Impact factor: 3.808

4.  Quantitative structure-activity relationship studies on nitrofuranyl anti-tubercular agents.

Authors:  Kirk E Hevener; David M Ball; John K Buolamwini; Richard E Lee
Journal:  Bioorg Med Chem       Date:  2008-07-29       Impact factor: 3.641

5.  Structure-activity relationships of antitubercular nitroimidazoles. 2. Determinants of aerobic activity and quantitative structure-activity relationships.

Authors:  Pilho Kim; Sunhee Kang; Helena I Boshoff; Jan Jiricek; Margaret Collins; Ramandeep Singh; Ujjini H Manjunatha; Pornwaratt Niyomrattanakit; Liang Zhang; Michael Goodwin; Thomas Dick; Thomas H Keller; Cynthia S Dowd; Clifton E Barry
Journal:  J Med Chem       Date:  2009-03-12       Impact factor: 7.446

6.  Dequalinium, a new inhibitor of Mycobacterium tuberculosis mycothiol ligase identified by high-throughput screening.

Authors:  Maria-Teresa Gutierrez-Lugo; Heather Baker; Joseph Shiloach; Helena Boshoff; Carole A Bewley
Journal:  J Biomol Screen       Date:  2009-06-12

7.  Early diagnosis and effective treatment regimens are the keys to tackle antimicrobial resistance in tuberculosis (TB): A report from Euroscicon's international TB Summit 2016.

Authors:  Arundhati Maitra; Tengku Karmila Kamil; Monisha Shaik; Cynthia Amaning Danquah; Alina Chrzastek; Sanjib Bhakta
Journal:  Virulence       Date:  2016-11-04       Impact factor: 5.882

8.  Antitubercular Nitroimidazoles Revisited: Synthesis and Activity of the Authentic 3-Nitro Isomer of Pretomanid.

Authors:  Andrew M Thompson; Muriel Bonnet; Ho H Lee; Scott G Franzblau; Baojie Wan; George S Wong; Christopher B Cooper; William A Denny
Journal:  ACS Med Chem Lett       Date:  2017-11-13       Impact factor: 4.345

9.  Development of (6 R)-2-Nitro-6-[4-(trifluoromethoxy)phenoxy]-6,7-dihydro-5 H-imidazo[2,1- b][1,3]oxazine (DNDI-8219): A New Lead for Visceral Leishmaniasis.

Authors:  Andrew M Thompson; Patrick D O'Connor; Andrew J Marshall; Adrian Blaser; Vanessa Yardley; Louis Maes; Suman Gupta; Delphine Launay; Stephanie Braillard; Eric Chatelain; Baojie Wan; Scott G Franzblau; Zhenkun Ma; Christopher B Cooper; William A Denny
Journal:  J Med Chem       Date:  2018-03-06       Impact factor: 7.446

Review 10.  Chemical Aspects of Human and Environmental Overload with Fluorine.

Authors:  Jianlin Han; Loránd Kiss; Haibo Mei; Attila Márió Remete; Maja Ponikvar-Svet; Daniel Mark Sedgwick; Raquel Roman; Santos Fustero; Hiroki Moriwaki; Vadim A Soloshonok
Journal:  Chem Rev       Date:  2021-03-16       Impact factor: 60.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.